

***Fiscal Year 2023 (FY23) Department of Defense Melanoma Research Program (MRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Idea Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> HT9425-23-MRP-IA</p>	<p><i>*Updated for FY23*</i> Investigators must be at or above the level of Postdoctoral Fellow or equivalent.</p> <p>Principal Investigators (PIs) new to the melanoma field are encouraged.</p>	<ul style="list-style-type: none"> <li>• <b><i>Preproposal is required; application submission is by invitation only.</i></b></li> <li>• Supports new ideas that represent innovative, high-risk/high-gain approaches to melanoma research that are beyond an incremental advancement.</li> <li>• Emphasis on innovation and impact.</li> <li>• <b>Must</b> address at least one of the FY23 MRP Focus Areas.</li> <li>• <b><i>Preliminary data are discouraged.</i></b> Inclusion of preliminary data other than serendipitous findings is <b>not</b> consistent with the exploratory/innovative nature of this award.</li> <li>• <b><i>Clinical trials are not allowed.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$500,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> July 10, 2023 5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b> September 22, 2023 11:59 p.m. ET</p>
<p><b>Melanoma Academy Scholar Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> HT9425-23-MRP-MASA</p>	<p><i>*Updated for FY23*</i> Investigators must be within 7 years of their first faculty-level appointment as of the full application submission deadline.</p>	<ul style="list-style-type: none"> <li>• <b><i>A letter of intent is required; an invitation to submit a full application is not required.</i></b></li> <li>• Supports the addition of new Scholars to the unique, interactive virtual <u>Melanoma Academy</u> that provides intensive mentoring, national networking, collaborations, and a peer group for early-career melanoma investigators.</li> <li>• Requires a Career Guide who is an experienced melanoma researcher with melanoma cancer funding.</li> <li>• The Career Guide is not required to be at the same institution as the Scholar.</li> <li>• The Career Guide must be committed to participating in the Melanoma Academy, including serving in advisory roles as requested by Academy Leadership.</li> <li>• <b>Must</b> address at least one of the FY23 MRP Focus Areas.</li> <li>• <b><i>Preliminary data are not required.</i></b></li> <li>• <b><i>Clinical trials are not allowed.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$550,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> August 31, 2023 5:00 p.m. ET</p> <p><b>Application:</b> September 22, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Mid-Career Accelerator Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT9425-23-MRP-MCAA</p>	<p>Investigators must be Assistant or Associate Professors (or equivalents) <b>at least 7 years</b> from their first faculty-level appointment.</p> <p><b>Instructors and Full Professors (or equivalents) are <u>not</u> eligible.</b></p>	<ul style="list-style-type: none"> <li><b><i>A letter of intent is required; an invitation to submit a full application is not required.</i></b></li> <li>Supports mid-career researchers conducting impactful melanoma research.</li> <li><b>Must</b> address at least one of the FY23 MRP Focus Areas.</li> <li><b>Must</b> show evidence of at least one peer-reviewed source of extramural funding.</li> <li><b><i>Preliminary data relevant to melanoma are required.</i></b></li> <li><b><i>Clinical trials are not allowed.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$725,000</b> for direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> <li>The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> August 31, 2023 5:00 p.m. ET</p> <p><b>Application:</b> September 22, 2023 11:59 p.m. ET</p>
<p><b>Team Science Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT9425-23-MRP-TSA</p>	<p>At least two and up to three Investigators must partner in one overarching multidisciplinary research study.</p> <p>Independent Investigators must be at or above the level of Assistant Professor (or equivalent).</p> <p>Inclusion of at least one military, U.S. Department of Veterans Affairs, or Early-Career Investigator is encouraged.</p> <p>Postdoctoral fellows are <b>not</b> eligible to be Initiating nor Partnering PIs.</p>	<ul style="list-style-type: none"> <li><b><i>A letter of intent is required; an invitation to submit a full application is not required.</i></b></li> <li>Supports new or existing partnerships to address a research problem or question in a manner that would be unachievable through separate efforts.</li> <li>Intended to fund a broad range of studies including, but not limited to: <ul style="list-style-type: none"> <li>Correlative studies that are associated with an open/ongoing or completed clinical trial</li> <li>Research involving the analysis of large and/or complex melanoma datasets</li> <li>Projects focusing on bioengineering approaches to address diagnostics, high risk markers, dormancy, and/or metastasis</li> <li>Research seeking to better understand and/or reduce inequities and disparities that impact melanoma patients and/or caregivers.</li> </ul> </li> <li>Emphasis on synergy, multidisciplinary research, and impact.</li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$1,250,000</b> for direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> <li>The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> August 31, 2023 5:00 p.m. ET</p> <p><b>Application:</b> September 22, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<ul style="list-style-type: none"> <li>Applicants are encouraged but not required to collaborate with the melanoma community (e.g., melanoma patients, survivors, caregivers) to optimize research impact and translatability through inclusion of a patient advocate, partnership with a community-supporting organization, or establishment of a community advisory board.</li> <li><b>Must</b> address at least one of the FY23 MRP Focus Areas.</li> <li><b>Preliminary data are required.</b></li> <li><b>Clinical trials are not allowed.</b></li> </ul>		
<p><b>Focused Program Award – Rare Melanomas</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT9425-23-MRP-FPA-RM</p>	<p>Independent Investigators must be at or above the level of Associate Professor (or equivalent).</p> <p>Project Leader(s) for the complementary and synergistic research project(s) must be at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> <li><b>A letter of intent is required; an invitation to submit a full application is not required.</b></li> <li>Applications may propose projects across the entire research spectrum (biology, etiology, prevention, diagnosis and detection, prognosis, treatment, and quality of life) and <b>must</b> address a critical unmet need relevant to <b>rare melanomas</b> (uveal, acral, mucosal, pediatric, etc.).</li> <li>Supports a synergistic, multidisciplinary research program of at least two but not more than three distinct but complementary projects addressing an overarching question relevant to <b>rare melanomas</b>.</li> <li>Individual research projects may range from exploratory, hypothesis-developing studies through clinical trials.</li> <li>The research team assembled by the PI should be highly qualified and multidisciplinary, with an identified Project Leader(s) for the complementary and synergistic research project(s).</li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$2,000,000</b> for direct costs.</li> <li>The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> August 31, 2023 5:00 p.m. ET</p> <p><b>Application:</b> September 22, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<ul style="list-style-type: none"><li data-bbox="850 147 1381 358">• Applicants are encouraged, but not required, to collaborate with the rare melanoma community to optimize research impact and translatability through inclusion of a patient advocate, partnership with a community-supporting organization, or establishment of a community advisory board.</li><li data-bbox="850 367 1178 391">• <i>Clinical trials are allowed.</i></li></ul>		